79 related articles for article (PubMed ID: 22737769)
1. Hormone copycats.
Gebel E
Diabetes Forecast; 2012 Jun; 65(6):36, 38-9. PubMed ID: 22737769
[No Abstract] [Full Text] [Related]
2. Exenatide for once-weekly administration.
Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
[TBL] [Abstract][Full Text] [Related]
3. Challenges and strategies for moving patients to injectable medications.
Siminerio L
Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
[No Abstract] [Full Text] [Related]
4. Using prandial insulin to achieve glycemic control in type 2 diabetes.
Dailey GE
J Fam Pract; 2007 Sep; 56(9):735-42. PubMed ID: 17764645
[No Abstract] [Full Text] [Related]
5. Exenatide once weekly in type 2 diabetes mellitus.
Bischoff LA; Jabbour SA; Miller JL
Expert Opin Pharmacother; 2011 Jun; 12(8):1297-1303. PubMed ID: 21548720
[No Abstract] [Full Text] [Related]
6. Once-weekly glucagon-like peptide 1 receptor agonists.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
[TBL] [Abstract][Full Text] [Related]
8. [Basal insulin and liraglutide combined in a pen].
Rausch R
Med Monatsschr Pharm; 2015 Apr; 38(4):154-6. PubMed ID: 26364391
[No Abstract] [Full Text] [Related]
9. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Fabreegas B
Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
[No Abstract] [Full Text] [Related]
10. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
[TBL] [Abstract][Full Text] [Related]
11. Longacting exenatide in diabetes: DURATION-3.
Misra A; Joshi S
Lancet; 2010 Jun; 375(9733):2198-9. PubMed ID: 20609957
[No Abstract] [Full Text] [Related]
12. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 analogues for type 2 diabetes.
Wilding JP; Hardy K
BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
[No Abstract] [Full Text] [Related]
14. [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
Ahrén B
Lakartidningen; 2007 Dec; 104(49-50):3763-4. PubMed ID: 18214322
[No Abstract] [Full Text] [Related]
15. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
Kern W
MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
[No Abstract] [Full Text] [Related]
16. Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
Anderson ZL; Clements JN
JAAPA; 2014 Jun; 27(6):44-6. PubMed ID: 24853156
[TBL] [Abstract][Full Text] [Related]
17. Targeting the incretin system in type 2 diabetes mellitus.
Potenza M; Rayfield EJ
Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
[TBL] [Abstract][Full Text] [Related]
18. Extended-release exenatide (Bydureon) for type 2 diabetes.
Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
[No Abstract] [Full Text] [Related]
19. Byetta update: what we've learned from experience.
Cornell S; Todd T
Diabetes Self Manag; 2010; 27(2):28, 30-1. PubMed ID: 20405747
[No Abstract] [Full Text] [Related]
20. Exenatide (Byetta) for type 2 diabetes.
Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
